BACKGROUND: Combined cisplatin chemotherapy and cranial irradiation for treatment of medulloblastoma in children can cause significant ototoxicity and impair cognitive function and quality of life. We have previously demonstrated the conformal technique of intensity-modulated radiation therapy (IMRT) to reduce ototoxicity, however, it has been suggested that IMRT may increase risk of cognitive deficits compared to conventional radiation therapy (CRT). This study compared the impact of the two treatments on measures of neurocognitive functioning. PROCEDURE: Twenty-five pediatric patients with medulloblastoma were treated either with CRT or IMRT. In addition they received neurocognitive assessments to evaluate long-term functional outcome. Statistical analyses between the two groups were conducted to compare levels and profiles of performance on tests not confounded with hearing loss. RESULTS: When compared to CRT, children treated with IMRT did not perform more poorly on any of the measures. Both groups' mean performance was significantly lower than published norms on several of the measures employed. CONCLUSION: The benefit of reduced ototoxicity with IMRT does not appear to be at the cost of a decline in nonverbal intellectual abilities, visual-spatial skills, processing speed, or fine motor dexterity when compared to CRT in children with medulloblastoma.
BACKGROUND: Combined cisplatin chemotherapy and cranial irradiation for treatment of medulloblastoma in children can cause significant ototoxicity and impair cognitive function and quality of life. We have previously demonstrated the conformal technique of intensity-modulated radiation therapy (IMRT) to reduce ototoxicity, however, it has been suggested that IMRT may increase risk of cognitive deficits compared to conventional radiation therapy (CRT). This study compared the impact of the two treatments on measures of neurocognitive functioning. PROCEDURE: Twenty-five pediatric patients with medulloblastoma were treated either with CRT or IMRT. In addition they received neurocognitive assessments to evaluate long-term functional outcome. Statistical analyses between the two groups were conducted to compare levels and profiles of performance on tests not confounded with hearing loss. RESULTS: When compared to CRT, children treated with IMRT did not perform more poorly on any of the measures. Both groups' mean performance was significantly lower than published norms on several of the measures employed. CONCLUSION: The benefit of reduced ototoxicity with IMRT does not appear to be at the cost of a decline in nonverbal intellectual abilities, visual-spatial skills, processing speed, or fine motor dexterity when compared to CRT in children with medulloblastoma.
Authors: Yin Ting Cheung; Tara M Brinkman; Chenghong Li; Yasmin Mzayek; Deokumar Srivastava; Kirsten K Ness; Sunita K Patel; Rebecca M Howell; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Natl Cancer Inst Date: 2018-04-01 Impact factor: 13.506
Authors: M Balducci; S Chiesa; D Chieffo; S Manfrida; N Dinapoli; A Fiorentino; F Miccichè; V Frascino; C Anile; V Valentini; B De Bari Journal: J Neurooncol Date: 2011-07-31 Impact factor: 4.130
Authors: Maru Barrera; Eshetu G Atenafu; Fiona Schulte; Ute Bartels; Lillian Sung; Laura Janzen; Joanna Chung; Danielle Cataudella; Kelly Hancock; Amani Saleh; Douglas Strother; Dina McConnell; Andrea Downie; Juliette Hukin; Shayna Zelcer Journal: Support Care Cancer Date: 2017-04-14 Impact factor: 3.603
Authors: Tara M Brinkman; Wilburn E Reddick; Joshua Luxton; John O Glass; Noah D Sabin; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Neuro Oncol Date: 2012-09 Impact factor: 12.300
Authors: Wilburn E Reddick; Delaram J Taghipour; John O Glass; Jason Ashford; Xiaoping Xiong; Shengjie Wu; Melanie Bonner; Raja B Khan; Heather M Conklin Journal: Pediatr Blood Cancer Date: 2014-01-25 Impact factor: 3.167
Authors: Gregory T Armstrong; Neelam Jain; Wei Liu; Thomas E Merchant; Marilyn Stovall; Deo Kumar Srivastava; James G Gurney; Roger J Packer; Leslie L Robison; Kevin R Krull Journal: Neuro Oncol Date: 2010-08-17 Impact factor: 13.029
Authors: Florian Sterzing; Eva M Stoiber; Simeon Nill; Harald Bauer; Peter Huber; Jürgen Debus; Marc W Münter Journal: Radiat Oncol Date: 2009-09-23 Impact factor: 3.481
Authors: Gregory M Shackleford; Min Y Mahdi; Rex A Moats; Debra Hawes; Hung C Tran; Jonathan L Finlay; Tuan Q Hoang; Ellis F Meng; Anat Erdreich-Epstein Journal: PLoS One Date: 2019-01-04 Impact factor: 3.240